OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 19,656 Cr.
- Current Price ₹ 1,718
- High / Low ₹ 1,800 / 1,163
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE -11.8 %
- ROE -45.6 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -48.5% over last 3 years.
- Debtor days have increased from 73.5 to 117 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 21 | 128 | 39 | 172 | |
| 93 | 132 | 199 | 254 | |
| Operating Profit | -71 | -4 | -161 | -82 |
| OPM % | -334% | -3% | -415% | -48% |
| 1 | -128 | -526 | -143 | |
| Interest | 16 | 46 | 48 | 89 |
| Depreciation | 34 | 53 | 66 | 76 |
| Profit before tax | -121 | -231 | -800 | -391 |
| Tax % | 0% | -0% | 0% | 0% |
| -121 | -231 | -800 | -391 | |
| EPS in Rs | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 100% |
| TTM: | 344% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -49% |
| Last Year: | -46% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 4 |
| Reserves | 774 | 1,009 | 781 | 392 | 401 |
| 386 | 1,182 | 864 | 571 | 612 | |
| 96 | 248 | 365 | 459 | 266 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 1,283 |
| 633 | 1,231 | 1,361 | 863 | 972 | |
| CWIP | 431 | 490 | 334 | 188 | 43 |
| Investments | 0 | 0 | 4 | 20 | 11 |
| 195 | 722 | 314 | 356 | 257 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 1,283 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| -118 | -416 | -163 | -107 | |
| -207 | -692 | -68 | 511 | |
| 381 | 1,162 | 118 | -391 | |
| Net Cash Flow | 56 | 54 | -112 | 13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 |
| Inventory Days | 87 | 615 | 258 | |
| Days Payable | 762 | 420 | 163 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 |
| Working Capital Days | -1,085 | 271 | -1,953 | -259 |
| ROCE % | -3% | -12% | -12% |
Documents
Announcements
- Closure of Trading Window 11h
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
13 Mar - Draft order for tax adjustments of INR 425.95 Mn.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 Mar - Schedule of analyst meeting on March 07, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 Feb - Appointment of three new independent directors at OneSource.
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Feb - Resignation of Mahadevan Narayanamoni from OneSource Specialty Pharma.
Annual reports
No data available.
Concalls
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.